EP Patent

EP2409690A2 — Improved stability of progestogen formulations

Assigned to Novo Nordisk Health Care AG · Expires 2012-01-25 · 14y expired

What this patent protects

In a preparation for hormone replacement therapy having a low content of progestogen, the stability of the progestogen component can be enhanced by using a cellulosic binder, for example hydroxypropylcellulose, in stead of a non-cellulosic binder.

USPTO Abstract

In a preparation for hormone replacement therapy having a low content of progestogen, the stability of the progestogen component can be enhanced by using a cellulosic binder, for example hydroxypropylcellulose, in stead of a non-cellulosic binder.

Drugs covered by this patent

Patent Metadata

Patent number
EP2409690A2
Jurisdiction
EP
Classification
—
Expires
2012-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk Health Care AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.